Correction: Neurol Ther (2024) 13:535–549 10.1007/s40120-024-00597-7
In Fig. 3 of this article, the top row of the Forest plot should show the right end of the confidence interval to align with a value of 0.71; the correct figure is shown below (Fig. 3).
Fig. 3.
Forest plot of NMA results for time-to-first relapse with ravulizumab versus alternate interventions in adults with AQP4-Ab+ NMOSD. In SAkuraSky and PREVENT, background IST such as azathioprine, mycophenolate mofetil, and glucocorticoids were allowed, whereas IST was explicitly excluded from the N-MOmentum and SAkuraStar population. AQP4-Ab+ anti-aquaporin-4 antibody-positive, CrI credible interval, IST immunosuppressive therapy, NMOSD neuromyelitis optica spectrum disorder
The original article has been corrected.